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Background/Aims: Although carcinoid tumors usually have good prognosis, early and specific diagnosis is
important. Computed tomography and magnetic resonance imaging do not provide findings that are specific for
carcinoids, and somatostatin receptor scintigraphy suffers from low spatial resolution. 18-Fluorodeoxyglucose
positron emission tomography/computed tomography (
18F-FDG PET/CT) has limited sensitivity for carcinoids due
to low uptake of the marker. A PET/CT system that uses the somatostatin receptor-based PET tracer 1,4,7,10-
tetraazacyclododecane-N
I,N
II,N
III,N
IIII-tetraacetic acid (D)-Phe
1-thy
3-octreotide (
68Ga-DOTATOC) has also been used
in the evaluation of carcinoids, although information regarding its use for the detection of primary pulmonary
carcinoids is limited. Thus, we investigated the value of 
68Ga-DOTATOC PET/CT for the diagnosis of primary
pulmonary carcinoid tumors.
Methods: This was a retrospective analysis of patients with primary pulmonary tumors who underwent 
68Ga-
DOTATOC PET/CT. All the patients had a histopathologic diagnosis of carcinoid. The rate of detection of primary
pulmonary carcinoid tumors using 
68Ga-DOTATOC PET/CT was assessed.
Results: Twenty patients were diagnosed as having carcinoid, and 19 tumors showed significant uptake on 
68Ga-
DOTATOC (detection rate, 95%). The maximal standardized uptake value (SUVmax) ranged from 1.1 to 66, with a
median value of 21.6. In one patient, 
68Ga-DOTATOC PET/CT revealed additional lesions.
Conclusions: Our results demonstrate that 
68Ga-DOTATOC PET/CT is useful in the evaluation of primary
pulmonary carcinoids and should be included in the diagnostic work-up of these patients. (Korean J Intern Med
2010;25:386-391)
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INTRODUCTION
Carcinoid tumors, which were first described in 1888 by
Lubarsch [1], represent 2% of all lung tumors [2]. While
patients with carcinoids usually have a good prognosis,
early and specific diagnosis is crucial. Various methods are
used to diagnose pulmonary carcinoids, including tumor
markers, computed tomography (CT), magnetic
resonance imaging (MRI), somatostatin receptor
scintigraphy (SRS), iodine-131-meta-iodobenzylguanidine
scintigraphy, positron emission tomography (PET), and
histopathologic examination. Tumor markers are not very
sensitive for this purpose [3], CT and MRI do not give
findings that are specific for carcinoids [4], and SRS
suffers from low spatial resolution [5]. 18-Fluorodeoxygl-
ucose positron emission tomography/computed
tomography (
18F-FDG PET/CT) usually shows low uptake
of the marker by carcinoids, and thus has low sensitivity
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for this type of tumor [6-8].  
PET/CT with 1,4,7,10-tetraazacyclododecane-N
I, N
II,
N
III, N
IIII-tetraacetic acid (D)-Phe
1-thy
3-octreotide (
68Ga-
DOTATOC PET/CT) has also been used to evaluate
carcinoid tumors. Initial reports of its use have been
encouraging, although data on the application of this
system to diagnose pulmonary carcinoids are limited [9-
11]. 
We applied 
68Ga-DOTATOC PET/CT to 20 patients with
primary pulmonary carcinoids, which is the largest series
of patients to be analyzed in this way.
METHODS
A retrospective analysis of the 
68Ga-DOTATOC PET/CT
findings of patients with pulmonary tumors, performed at
our institution during a span of 3 years, was done.
Approval for this study was obtained from the
institutional ethics committee, and the guidelines
established by the committee were followed during the
trial. All the patients gave written informed consent at the
time of their clinical work-up. Consent was obtained from
the parents or legal guardians for patients < 18 years of
age. All the necessary precautions were taken to protect
the identities of the patients in the study. 
In total, 20 patients with pulmonary carcinoids were
enrolled, and their medical records were analyzed. All the
patients underwent a thorough clinical examination,
hemogram, routine biochemistry, chest X-ray, contrast-
enhanced CT (CECT) of the chest and upper abdomen,
68Ga-DOTATOC PET/CT, pulmonary function testing, and
bronchoscopy, together with biopsy when feasible,
followed by surgery (except for case 15). The tissues
diagnosis involved histopathologic examination of either
the biopsy or the surgical specimen. The detection rate of
68Ga-DOTATOC PET/CT for these tumors was calculated
retrospectively.
68Ga-DOTATOC PET/CT protocol
PET scans were performed on a dedicated PET/CT
scanner (Siemens Biograph 2; Siemens, Erlanger,
Germany), using lutetium oxyorthosilicate (LSO;
Lu2SiO5:Ce) detectors with attenuation coefficient of 0.89
cm
-1, photo-fraction of 30%, and decay constant of 40
nanoseconds. The energy resolution at 511 KeV was 10,
with spatial resolution of 6 mm. After fasting for at least 4
hours and verification of the serum glucose level, the
patient was kept in a resting state in a quiet room, and
68Ga-DOTATOC PET/CT was performed 45 to 60 minutes
after intravenous injection of 74 to 111 MBq of the
radiotracer. CT acquisition was performed on a spiral dual
slice CT with a slice thickness of 4 mm and a pitch of 1.
The image was acquired using a matrix of 512 ×512 pixels,
with a pixel size of about 1 mm. After the transmission
scan, three-dimensional PET acquisition was carried out
for 5 to 8 minutes per bed position. The PET data were
acquired using a matrix of 128 × 128 pixels. CT-based
attenuation correction of the emission images was
employed.
The PET images were reconstructed through an
iterative method of ordered subset expectation
maximization (two iterations and eight subsets) using a 5-
mm filter. After completion of PET acquisition, the
reconstructed, attenuation-corrected PET images, CT
images, and fused images of matching pairs of PET and
CT images were available for review in the axial, coronal,
and sagittal planes, as well as in maximum intensity
projections and three-dimensional cine mode.
Two experienced nuclear medicine physicians, who
were blinded to the structural imaging findings and
clinical findings of the patients, evaluated the data
independently. PET images were assessed for areas of
increased radiotracer uptake. The corresponding areas in
the CT images and fused PET/CT images were identified
for corroboration. If the lesion showed a definite increase
in DOTATOC accumulation compared with the
background, it was interpreted as being visually positive
for a viable tumor. For semi-quantitative analysis, a region
of interest (ROI) was drawn around the site of abnormal
uptake in the consequent four to six PET/CT slices. The
slice that showed maximal uptake in the ROI was chosen
for quantitative measurement of metabolic activity/
uptake of the tracer (SUV). From these ROIs, the SUVmax
was calculated according to the formula:
SUVmax = ROI (at the pixel with maximum uptake,
MBq/g) / (injected dose, MBq / body weight, g).
RESULTS 
The study involved 20 patients (11 males and nine
females) with a mean age of 32.7 years (range, 16 to 53).
The patients' characteristics and the structural imaging
and
68Ga-DOTATOC PET/CT findings are summarized in
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Among the patient, cough was the commonest
symptom (n = 19), followed by expectoration (n = 17),
hemoptysis (n = 14), dyspnea (n = 7), and chest pain (n =
4). One patient had Cushing's syndrome (case 5). 
Chest X-rays revealed either collapse or opacity in 19
patients, and the findings were normal in one patient
(case 5). CECT of the chest revealed the primary lesion in
every patient. All the lesions exhibited contrast
enhancement. No additional lesions were found in any
patient. Most of the tumors were detected on the patient's
right side (n = 15).
68Ga-DOTATOC PET/CT, by virtue of its CT component,
revealed all the lesions anatomically. Overall, 19/20
tumors showed significant uptake of 
68Ga-DOTATOC,
giving visual positivity and a SUVmax value > 2.5. Thus, the
detection rate for 
68Ga-DOTATOC PET/CT was 95%. The
median SUVmax value was 21.6 (range, 1.1 to 66.0). The
lowest SUVmax value for tumors with significant uptake of
the radiotracer was 4.7.  
Of the 20 patients, 13 had typical carcinoid tumors, and
seven had atypical carcinoid tumors. All the typical
carcinoids showed significant uptake of Ga-68 DOTATOC.
One atypical carcinoid lacked any significant uptake of
Ga-68 DOTATOC (case 18). The typical carcinoids also
showed significantly higher levels of Ga-68 DOTATOC
uptake than the atypical carcinoids. In one patient (case
15), 
68Ga-DOTATOC PET/CT facilitated the detection of
additional lesions, which showed significant radiotracer
uptake, in the mediastinal lymph nodes, pancreas,
thyroid, and pituitary, none of which was identified in the
conventional CT. Biopsies of the mediastinal lymph nodes
confirmed the presence of metastatic deposits of the
carcinoid tumor.
DISCUSSION
Pulmonary carcinoids are usually detected in structural
imaging systems such as CT or MRI, which detect a space-
occupying lesion. However, because these techniques do
not provide information on the specific characteristics that
would allow unambiguous identification of the tumor as
carcinoid, they have low specificity [4]. Functional
imaging has been used in the work-up of patients with
carcinoids. 
18F-FDG PET/CT suffers from low sensitivity
due to low uptake of the tracer by carcinoids, which is
Table 1. Patients' characteristics and results of structural imaging and 
68Ga-DOTATOC PET/CT imaging
Patient no. Age, yr Sex CT
68Ga-DOTATOC PET/CT
Tumor size, cm Tumor site SUVmax
1 40 F 3.2 × 1.8 Right intermediate bronchus 23.2
2 16 F 1.5 × 0.9 Left main bronchus 58
3 35 F 3.8 × 3.7 Right main bronchus 43
4 44 M 2.5 × 5.0 Right lower lobe bronchus 11
5 40 M 1.0 × 0.7 Posterior basal segment of left lower lobe 8.8
6 23 M 6.8 × 5.0 Right hilar area 33
7 40 F 3.6 × 3.4 Right lower lobe bronchus 60
8 45 M 4.0 × 6.0 Left main bronchus 33
9 25 F 1.8 × 1.5 Right main bronchus 20
10 22 M 3.0 × 2.5 Right intermediate bronchus 43
11 45 M 3.4 × 4.7 Right intermediate bronchus 33
12 19 F 3.3 × 2.2 Right intermediate bronchus 45
13 22 M 3.2 × 2.8 Right main bronchus 66
14 53 M 8.0 × 7.0 Right main bronchus 6.3
15 40 F 5.0 × 7.1 Right main bronchus + calcification 18.5
16 34 M 4.0 × 4.8 Right lower lobe 12.3
17 16 F 1.5 × 1.5 Left upper lobe bronchus 13.9
18 31 M 3.4 × 4.7 Right hilum at lower lobe bronchial division 1.1
19 29 F 5.5 × 1.5 Left main bronchus 10.3
20 36 M 4.4 × 3.8 Right main bronchus 4.7
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related to their poor metabolism. Rege  et al. [6] evaluated
a patient with a pulmonary carcinoid and history of
ectopic adrenocorticotrophic hormone secretion using 
18F-
FDG PET; the lesion was found to be hypometabolic for
18F-FDG. Erasmus et al. [7] evaluated seven cases of
pulmonary carcinoids using 
18F-FDG PET and found that
three of these patients were visually negative, three
patients were hypometabolic and were erroneously
categorized as benign nodules, and one patient was
visually positive. Kruger et al. [8] evaluated pulmonary
carcinoids in 13 patients and found that 6/12 (50%) had
typical carcinoids with SUVmax < 2.5. 
DOTATOC has high affinities for SSR2 and SSR3 and
lower affinity for SSR5. 
68Ga-DOTATOC PET/CT has been
shown to be highly accurate in the diagnosis of
neuroendocrine tumors, meningiomas, thyroid
malignancies, and prostatic cancers. It has also been used
successfully to evaluate primary lung cancers, particularly
the small-cell form. The high resolution of PET enables
high detection rates for small tumors. As with most
investigative tools, DOTATOC PET/CT also has
limitations. It can theoretically show positivity for non-
tumor tissues, such as those in the pancreas (especially the
uncinate process), in the pituitary gland, and in chronic
inflammatory conditions (e.g., granulomatous diseases
and sarcoidosis). Nonetheless, this technique represents
an advance in diagnostic oncology.
Because carcinoid tumors are rich in somatostatin
receptors (SSR), they typically show high-level uptake of
68Ga-DOTATOC. Although various studies have
demonstrated the utility of 
68Ga-DOTATOC PET/CT in the
evaluation of carcinoids, little information is available on
the use of this tool for pulmonary carcinoids, especially
primary carcinoids in the lungs. The value of 
68Ga-
DOTATOC PET/CT for the diagnosis of primary pulmonary
carcinoids remains to be established due to the lack of
specific studies.
Hofmann et al. [9] compared the diagnostic values of
111In-octreotide scintigraphy and 
68Ga-DOTATOC PET to
morphologic imaging in eight patients with histologically
proven metastatic carcinoid tumors (six abdominal and
two bronchial carcinoids). 
68Ga-DOTATOC PET identified
all the lesions, whereas 
111In-octreotide scintigraphy
identified only 85% of the lesions. Koukouraki et al. [10]
used 
68Ga-DOTATOC PET to evaluate 15 cases of carcinoid
tumors, including two cases of pulmonary carcinoids, and
reported an overall sensitivity of 92%. Gabriel et al. [11]
used 
68Ga-DOTATOC PET to evaluate 84 patients with
neuroendocrine tumors, including five patients with
bronchial carcinoids, and reported a sensitivity of 97%,
specificity of 92%, and an overall accuracy of 96%. These
results were far superior to those obtained using SPECT or
CT. 
Other 
68Ga-labeled peptides with profiles similar to that
of 
68Ga-DOTATOC have been used to evaluate pulmonary
carcinoids. Ambrosini et al. [12] evaluated 11 patients with
bronchial carcinoids using PET/CT with 
68Ga-DOTANOC
(1,4,7,10-tetraazacyclododecane-N
I,N
II,N
III,N
IIII-tetraacetic
acid-1-Nal3-octreotide). There were no false-positive
findings, and 
68Ga-DOTANOC PET/CT detected more
lesions than did CT (37 vs. 21). Kayani et al. [13] evaluated
18 patients with pulmonary neuroendocrine tumors using
PET/CT with 
68Ga-DOTATATE (1,4,7,10-tetraazacy-
clododecane-N
I,N
II,N
III,N
IIII- tetraacetic acid (D)-Phe
1-thy
3-
octreotate) and 
18F-FDG PET/CT; they detected 11 cases of
typical carcinoid, two cases of atypical carcinoid, two cases
Figure 1. CT (A), 
68Ga-DOTATOC PET whole-body projection image (B) and fused 
68Ga-DOTATOC PET/CT image (C) for case 3,
showing intense uptake of the tracer by the tumor (arrow). The SUVmax value is 43. SUVmax, maximal standardized uptake value.
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of diffuse idiopathic pulmonary neuroendocrine
hyperplasia, one small-cell neuroendocrine tumor, one
large-cell neuroendocrine tumor, and one case of
adenocarcinoma with neuroendocrinal differentiation.
They found that the majority of the carcinoids showed
significant uptake of 
68Ga-DOTATATE. 
In the present study, all the patients presented with a
primary tumor. There was significant uptake of
68Ga-
DOTATOC in 19/20 patients (detection rate of 95%), and
these findings corroborated the diagnosis of carcinoid. The
findings for a typical positive case are shown in Fig. 1. Case 5
had symptoms of Cushing's syndrome. CT demonstrated a
small, suspicious-looking lesion in the left lower lobar
parenchyma, but the finding was not conclusive.
Obtaining a biopsy was not possible owing to the small
size of the lesion. 
68Ga-DOTATOC uptake by the lesion was
high, supporting the diagnosis. Excision of the lesion
resulted in a complete clinical response for this patient.
The results obtained with CECT and 
68Ga-DOTATOC
PET/CT were concordant with respect to the primary
lesions. CECT did not reveal any lesions other that the
primary tumor in any of the patients. 
68Ga-DOTATOC
PET/CT detected additional lesions in case 15 (Fig. 2) and
facilitated tumor staging, prognostication, and decisions
as to the choice of treatment offered to this patient. The
tumor, which did not show any significant uptake of 
68Ga-
DOTATOC, was defined as an atypical carcinoid (case 18).
Atypical carcinoids are known to exhibit low-level
differentiation and decreased somatostatin receptor
expression, which may explain the lack of uptake on
68Ga-
DOTATOC PET/CT [13].
The present study, which is the largest conducted to
date for the evaluation of primary pulmonary carcinoids,
reveals that 
68Ga-DOTATOC PET/CT has a high detection
rate for primary pulmonary carcinoids. Although
histopathology remains the confirmatory modality, 
68Ga-
Figure 2. Whole-body projection image (A) and fused PET/CT images (B-D) for case 15 using
68Ga-DOTATOC PET and showing
tracer uptake by the thyroid (B, arrow), superior-mediastinal node (C, dotted arrow) and pancreas (D, bolded arrow).
A B
C
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DOTATOC PET/CT can provide highly useful guidance
during the evaluation of patients with pulmonary masses,
as compared with conventional investigative modalities. If
the tumor shows uptake on 
68Ga-DOTATOC PET/CT,
there is a high likelihood that it is carcinoid. Thus, the
clinician may be helped in resolving a dilemma that is
often encountered during the diagnosis of pulmonary
masses.
As 
68Ga-DOTATOC PET/CT provides both anatomical
information (by virtue of the CT component) and
information on the functional status of the tumor (by
virtue of the PET component), the need to perform a
separate CECT is eliminated. 
68Ga-DOTATOC PET/CT
also facilitates proper staging and planning of the
treatment modality to be offered to the patient. Moreover,
based on the results of the present study, it is superior to
CECT. 
68Ga-DOTATOC PET/CT can also be used to plan
eventual targeted radionuclide therapies and may help in
the selection of patients who are likely to benefit from
radio-immunotherapy with 
177Lu- or 
90Y-labeled
DOTATOC [10].
Therefore, 
68Ga-DOTATOC PET/CT represents an
important component of the diagnostic work-up for
patients with pulmonary carcinoids and should be used
more widely.
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